LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the ...
FOSTER CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today reported financial results for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback